At the news
? NEUTRALIMPACT 3/10 8-K filed Jun 29, 2026 at 08:30 ET
Alaunos Therapeutics announced new preclinical statistical analysis for ALN1003, showing lower liver weight after adjusting for body fat percentage in a 48-day DIO mouse study. The data is directionally consistent with prior liver marker and biomarker findings, but remains non-GLP preclinical with no human trials. The company had only ~$0.354M cash as of March 31, 2026, and will need additional financing to continue development.
- ALN1003-treated animals showed lower liver weight after adjustment for body fat percentage (ANCOVA p=0.000005; HC3 robust p=0.000015) in a 48-day DIO mouse study.
- Findings are directionally consistent with previously disclosed lower liver injury enzymes, lower NAFLD Activity Scores (NAS), lower HOMA-IR, and favorable adipose endocrine biomarkers.
- ALN1003 has not been evaluated in human clinical trials; safety and efficacy in humans not established.
- As of March 31, 2026, the company had cash and cash equivalents of approximately $0.354 million and intends to pursue additional financing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access